Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pier Luigi Temporelli has a total of 189 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Standard clinical and stress electrocardiogram variables to exclude left main and left main-equivalent disease: the MASTER study

    by Marco De Carlo, Marco Andrea Malanima, Laura Baglietto, Lorenzo Bazan, Sergio Berti, Paolo Calabrò, Luca Carmisciano, Alberto Ranieri De Caterina, Simona Fabozzo, Marco Fornili, et al.

    Background and Aims: A simple diagnostic method able to reliably exclude left main (LM) coronary artery disease (CAD) or LMCAD-equivalent would expand implementation of an initial non-invasive strategy in patients with chronic coronary syndrome (CCS). This study assessed the diagnostic utility of an approach using clinical and ECG stress testing (EST) variables in excluding LMCAD/LMCAD-equivalent in CCS patients. Methods: In a multicentre case-control study, CCS patients undergoing invasive coronary angiography (CAG) after a maximal EST were evaluated. Cases were patients with angiographic ≥ 50% LM stenosis or ≥70% stenosis of both proximal left anterior descending and proximal circumflex arteries, matched with similar patients without them (controls) in a 1:3 ratio. A risk model developed through logistic regression was internally and externally validated. Results: Three hundred and thirty-five cases were matched with 797 controls. The model area under the curve (AUC) was .78. Assuming LMCAD prevalence of 5% and a misclassification cost ratio of 1:100 (ratio of cost of performing CAG in a control to cost of not performing CAG in a case), negative predictive value was 98.2%. Thus, CAG could be safely avoided in 41% of patients, missing one LMCAD/LMCAD-equivalent diagnosis for every 58 CAGs safely spared in patients without them. Conclusions: Among CCS patients, LMCAD/LMCAD-equivalent can be excluded with high negative predictive value through a model based on clinical and EST parameters, allowing initial non-invasive management of most patients able to exercise. This approach is potentially useful particularly in communities where access to computed tomography coronary angiography is limited.


  • Fragility analysis of cardiovascular outcomes with finerenone in patients with Type 2 diabetes mellitus and chronic kidney disease

    by Marco Zuin, Claudio Bilato, Pier Luigi Temporelli, Fabrizio Oliva, Gianluigi Savarese, Marco Metra, Gerasimos Filippatos, Alberto Corsini, Samuel Z Goldhaber, Gregory Piazza

    Aims: Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, has been shown to reduce cardiovascular (CV) events in patients with Type 2 diabetes mellitus and chronic kidney disease. We aimed to quantify the robustness of its CV benefits in randomized controlled trials using fragility metrics coupled with conventional clinical effect measures. Methods: We systematically searched MEDLINE and Scopus (from inception to June 2025) for Phase 3/4 placebo-controlled randomized trials of finerenone in Type 2 diabetes mellitus and chronic kidney disease reporting dichotomous CV outcomes. Three studies were included: FIDELIO-DKD, FIGARO-DKD, and the pooled FIDELITY analysis. We extracted hazard ratios (HRs), absolute risk reduction, relative risk reduction, number needed to treat (NNT), fragility index (FI), reverse FI, fragility quotient (FQ), and reverse FQ for the primary composite CV outcome (CV death, non-fatal myocardial infarction, non-fatal stroke, heart failure hospitalization) and individual components. Results: The primary composite outcome was significantly reduced in FIDELIO-DKD (HR .86, NNT 56; FI 4, FQ .0007) and FIDELITY (HR .86, NNT 59; FI 38, FQ .002), but not FIGARO-DKD (HR .87; reverse FI 7, reverse FQ .0009). Among individual outcomes, heart failure hospitalization showed the most consistent and robust benefit (FIDELITY: HR .78, NNT 91; FI 23, FQ .001). Effects on CV death, myocardial infarction, and stroke were numerically favourable but statistically non-significant, with low reverse fragility indices. Conclusions: Finerenone significantly reduces heart failure hospitalization and modestly improves CV outcomes in Type 2 diabetes mellitus with chronic kidney disease, but effects on CV death, myocardial infarction, and stroke are fragile. Combining fragility metrics with standard efficacy measures offers a clearer view of the reliability of trial results.


  • Open Access

    Physical activity in hypertrophic cardiomyopathy: from proscription to prescription

    by Pier Luigi Temporelli, Marco Zuin

    Recent preclinical and clinical data suggest that moderate physical activity may be safe and beneficial in patients with hypertrophic cardiomyopathy (HCM). Evidence regarding a safe dose of high-intensity exercise remains limited; however, the marked heterogeneity in the morphology and pathophysiology of HCM implies that some individuals are capable of performing even vigorous exercise, including competitive high-intensity sports. Current data indicate that participation in intense exercise and competitive athletics may be considered in a carefully selected subset of predominantly adult patients with a low-risk profile. Studies evaluating the impact of vigorous exercise or moderate-to-high intensity competitive sports on the natural history of HCM remain few and are underpowered to definitively resolve this issue. Nonetheless, emerging evidence now supports a more liberal approach whereby—after appropriate selection, expert clinical evaluation, and shared decision-making—individuals with a low-risk profile may engage in high-intensity physical activity and competitive sports, leading active and fulfilling lives while minimizing risk.

  • Open Access

    Sustainable and effective lipid-lowering management: prevention strategies from the BRING-UP prevention study

    by Furio Colivicchi, Pier Luigi Temporelli, Francesco Fattirolli, Maurizio Giuseppe Abrignani, Alessandro Alonzo, Marcello Arca, Maurizio Averna, Daniele Bertoli, Paolo Calabrò, Leonardo Calò, et al.

    Aims: Adherence to guideline recommendations for secondary prevention appears to be inadequate, even in cardiology centres. To narrow the gap between guideline recommendations and what is implemented in clinical practice, we designed the BRING-UP Prevention project. Methods and results: BRING-UP Prevention is a nationwide, observational, prospective, multicenter study enrolling patients with a prior atherothrombotic event. The study consists of two 3-month enrolment phases followed by a 6-month follow-up, with each phase preceded by an educational intervention. Data presented here mainly focus on the percentage of patients at goal for LDL-cholesterol (LDL-C) (<55 mg/dL) at the 6-month follow-up in the recently completed first enrolment phase. Secondary endpoints are blood pressure, glycaemic and weight control, and smoking cessation. Over 3 months, 189 cardiology centres recruited 4790 patients. Follow-up data at 6 months were available for 4643 patients (97%) and LDL-C was available for 4334 of them. The rate of patients with LDL-C < 55 mg/dL increased from 33% to 58.1%, with absolute and relative increases of 25.1% and 76.1%, respectively. At 6 months, 94.9% of patients were prescribed statins. Atorvastatin and rosuvastatin were the most prescribed statins, mostly at high doses. Ezetimibe was prescribed in 84% of cases. PCSK9i monoclonal antibodies and inclisiran were prescribed in 8.3% of patients. Conclusion: BRING-UP prevention achieved its primary goal to increase the percentage of patients at the LDL-C goal, demonstrating that, in many patients, this goal can be achieved by increasing the use of low-cost therapies. ClinicalTrial.gov: NCT06275113


  • Robustness of randomized controlled trial evidence for SGLT2 inhibitors in heart failure with preserved and mildly reduced ejection fraction

    by Marco Zuin, Pierluigi Temporelli, Claudio Bilato, Alberto Corsini, Fabrizio Oliva, Gianluigi Savarese, Raffaele De Caterina


  • Alcoholic cardiomyopathy-attributed mortality in Europe, 2012–20

    by Marco Zuin, Fernando Domínguez, Chiara Dalla Valle, Alessandro Maloberti, Catia De Rosa, Marco Mojoli, Massimiliano Rizzo, Francesco Ciccirillo, Alfredo Madrid, Claudio Bilato, et al.

    Aims: Alcoholic cardiomyopathy (AC) is an important cause of cardiovascular disease worldwide. However, assessments of recent trends in the contribution of AC to European mortality are limited. To assess the trends in AC-attributable mortality in Europe from 2012 to 2020 across age, sex and European subregions. Methods and results: Alcoholic cardiomyopathy-attributed mortality data from 2012 to 2020 were obtained from the World Health Organization (WHO) mortality database, while alcohol consumption trends were sourced from the WHO NCD dataset. Age-adjusted mortality rates (AAMRs) were analysed using joinpoint regression to calculate average annual percentage change (AAPC) with 95% confidence intervals. A parallelism test was used to compare trends via pairwise joinpoint regression analysis. From 2012 to 2020, 504 096 subjects (387 387 men and 116 709 women) died from AC, equating to 634.5 deaths per 100 000 population. The relative AAMR decreased over the study period [AAPC: −4.7% (95% CI: −5.4 to −3.9), P < 0.001], especially in women compared with men (p for parallelism = 0.006). The decrease in AC-attributable mortality was greater among subjects aged 70 years and older compared with those younger than 70 (p for parallelism 0.001). The AAMRs for the AC-attributable mortality decreased in all European subregions except in the South. Analysis of the WHO NCD dataset revealed an average annual alcohol consumption of 10.8L in 2012 and 9.9L in 2020 in Europe, reflecting an approximately 8.3% decrease. Conclusion: Alcoholic cardiomyopathy-attributable mortality in Europe has declined over the past decade, paralleling a reduction in alcohol consumption.


  • Open Access

    Advances in Hypertension Management: Insights from the Latest European Guidelines

    by Marco Zuin, Chiara Tognola, Alessandro Maloberti, Gianfranco Parati, Stefania Angela Di Fusco, Vered Gil Ad, Donatella Armata, Chiara Dalla Valle, Furio Colivicchi, Claudio Bilato, et al.

    Arterial hypertension is one of the most common and preventable risk factors for cardiovascular disease and its related mortality. Currently, the prevalence of hypertension in different European countries appears to be around 30–45% of the general population, with a steep increase with ageing. Recent European guidelines have introduced novel recommendations for the management and treatment of hypertensive patients, with direct implications in daily clinical practice. Therefore, in this focused review, we will provide answers to the most common questions regarding the diagnosis, management and treatment of arterial hypertension according to the latest available European guidelines.


  • Open Access

    Oral semaglutide: an innovative paradigm in the management of cardiovascular risk in patients with Type 2 diabetes

    by Pier Luigi Temporelli

    Cardiovascular (CV) diseases (CVDs) remain a leading global health issue, causing about one-third of all deaths worldwide. Among modifiable CV risk factors (systolic blood pressure, non-HDL cholesterol, diabetes, body mass index, and smoking), diabetes is a leading one, accounting for established CVDs in 34.8% of diabetic patients, with an increasing prevalence of disease. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), like exenatide, liraglutide, albiglutide, dulaglutide, and semaglutide, initially developed for treatment of Type 2 diabetes, have shown CV benefits, and international guidelines recommend now GLP-1 RAs as preferred drugs for CV prevention in diabetic patients regardless of baseline HbA1c or metformin use. Among GLP-1 RAs, subcutaneous semaglutide has demonstrated cardio-metabolic risk factors reduction and efficacy in CV prevention. Development of oral semaglutide represents the evolution of the molecule. The PIONEER study programme confirmed the efficacy of oral semaglutide in reducing HbA1c, body weight, and cardio-metabolic risk factors as well as CV safety. Notably, independently by route of administration, semaglutide showed early CV benefits, suggesting mechanisms beyond glycaemic control or weight reduction. Semaglutide, combining potent cardio-metabolic effects with oral route, emerges as a pivotal treatment for high-risk Type 2 diabetes patients, offering comprehensive CV protection independent of HbA1c levels.


  • Open Access

    Two still unanswered questions about uric acid and cardiovascular prevention: Is a specific uric acid cut-off needed? Is hypouricemic treatment able to reduce cardiovascular risk?

    by Alessandro Maloberti, Valentina Colombo, Francesca Daus, Lorenzo De Censi, Maurizio Giuseppe Abrignani, Pier Luigi Temporelli, Giulio Binaghi, Furio Colivicchi, Massimo Grimaldi, Domenico Gabrielli, et al.


  • Open Access

    Role of glucagon-like peptide-1 agonists in obesity and heart failure with preserved ejection fraction

    by Pier Luigi Temporelli

    Heart failure with preserved ejection fraction (HFpEF) currently represents the majority of all heart failure cases in the community. Glucagon-like peptide-1 agonists represent a class of medications used to treat type 2 diabetes mellitus and, in some cases, obesity. This class includes semaglutide. In the available data from the Semaglutide Treatment Effect in People with Obesity (STEP) trials that were done, looking at weight loss effects of semaglutide, there was a 30–40% reduction in C-reactive protein levels, and that suggests that there is a significant anti-inflammatory effect. Recently, the STEP-HFpEF trial enrolled 529 non-diabetic patients with HFpEF and obesity who were randomly assigned to once-weekly semaglutide (2.4 mg) or placebo for 52 weeks. A statistically significant improvement in the quality of life score and in weight loss was observed. Statistically significant improvements were also seen in the 6 min walk distance, levels of C-reactive protein, and N-terminal pro–B-type natriuretic peptide levels. Interestingly, the Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity trial has shown that semaglutide produced a consistent reduction of around 20% vs. placebo across major cardiovascular event endpoints over the ∼3-year follow-up in patients with overweight or obesity and cardiovascular disease but not diabetes.